Merck & Co Inc. issued a statement on May 23, 2025, affirming its position regarding alternate dosing regimens for GARDASIL 9. The statement addresses discussions around a potential reduced dosing recommendation for the HPV vaccine.
The company's communication indicates ongoing engagement with regulatory bodies and public health organizations regarding optimal vaccination strategies. Merck has consistently provided data to support the efficacy and safety of its HPV vaccines across various dosing schedules.
This statement serves to clarify Merck's stance on the matter, without announcing a definitive change in policy or a new recommendation. It reflects the company's commitment to ensuring appropriate use of its vaccines while navigating evolving public health guidelines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.